Neopharm Ltd, Israel

Cannabinoids. Cannabidiol 100 mg/ml.
Oral sol. 100 ml . Seizures assoc. with Lennox-Gastaut Syndr. or Dravet Syndr.: start. dose 2.5 mg/kg twice daily. After 1 week, dosage can be incr. to a mainten. dosage of 5 mg/kg twice daily. Max. recommen. mainten. dosage is 10 mg/kg twice daily.
Seizures assoc. with Tuberous Scler. Cplex.: start. dose 2.5 mg/kg twice daily. Incr. the dose in weekly increm. of 2.5 mg/kg twice daily, as toler., to a recommen. mainten. dosage of 12.5 mg/kg twice daily. Adjunct. ther. of seizures assoc. with Lennox-Gastaut syndr. (LGS) or Dravet syndr. (DS) for pt. aged. 2 y and older. Adjunct. ther. of seizures assoc. with tuberous sclerosis complex (TSC) in pts. 1 year of age and older.
C/I: Hypersens.

Centrally Acting Sympathomimetics. Solriamfetol 75 mg, 150 mg.
FC tabs  7,28,56 X 75/150 mg
Narcolepsy: recomm. starting dose is 75 mg 1/d, max dd is 150 mg
OSA: recomm. starting dose is 37.5 mg 1/d, max dd is 150 mg
To improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy (with or w/ot cataplexy).
Also to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA ther., such as CPAP.
C/I: Hypersens. /MI within the past year, unstable angina pectoris, uncontrolled HT serious cardiac arrhythmias and other serious heart problems/
Concom. use of MAOI or within 14 days after MAOI has been discontinued